All In MedTech

Device Trial Radar · NCT05540457

Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)

Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis

Last checked: Nov 20, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Sep 22, 2022

Primary completion

Feb 9, 2024

Study completion Feb 9, 2024

Sponsor

Lead sponsor
The Rogosin InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Outset Medical; CareTaker Medical LLC
First posted
Sep 14, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, single center, open label, non-randomized, post-market study of the Tablo Hemodialysis System and VitalStream Monitor in participants with End-Stage KidneyDisease undergoing In-Center Hemodialysis.

Conditions

  • End Stage Renal Disease
  • End Stage Renal Disease on Dialysis
  • Dialysis Hypotension
  • Dialysis Induced Hypertension

Interventions

  • Intermittent Non-InvasiveBlood Pressure MonitorDevice

    Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis. Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Non-invasive Blood Pressure Monitor (NIPB) MeasurementsTime frame: 7 days from start of participation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Rogosin Institute

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.